Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Bayzed Health Group Partners With MicroPort Subsidiaries to Establish Specialized Cardiovascular and Surgical Robot Centers Across Hospital Network

Fineline Cube May 21, 2026
Company Deals

Medtronic to Acquire SPR Therapeutics for $650 Million, Expanding Chronic Pain Management Portfolio

Fineline Cube May 21, 2026
Company Deals

Bristol-Myers Squibb Partners With Anthropic to Deploy Claude AI Across Enterprise, Signaling Strategic Shift to Agentic Workflows

Fineline Cube May 21, 2026
Company Deals

CBC Group and Global Healthcare Opportunities Merge to Create $21 Billion Healthcare Investment Colossus

Fineline Cube May 20, 2026
Company Deals

Hybio Pharmaceutical Partners with Undisclosed Chinese Firms for GLP-1 API Commercialization in Americas Markets

Fineline Cube May 20, 2026
Policy / Regulatory

China Tightens Medical Insurance Personal Account Oversight with Mandatory “White List” for Retail Pharmacy Purchases

Fineline Cube May 19, 2026
Company Drug

Boehringer Ingelheim and Sino Biopharmaceutical Secure NMPA Conditional Approval for Hernexeos in First-Line HER2-Mutant NSCLC With 76% Response Rate

Fineline Cube May 21, 2026
Company Drug

Transcenta and Inhibrx Report 20% Response Rate for Ozekibart in Heavily Pretreated Colorectal Cancer, Following Recent FDA Filing for Chondrosarcoma

Fineline Cube May 21, 2026
Company

GSK’s Ma Zheng to Depart as Head of Communication and Government Affairs in China

Fineline Cube Aug 15, 2024

Ma Zheng, the head of communication and government affairs for GSK plc (NYSE: GSK) in...

Company Deals Medical Device

Shanghai Sanyou Medical to Acquire Full Control of SMTP Technology for RMB 415.7 Million

Fineline Cube Aug 15, 2024

Shanghai Sanyou Medical Co., Ltd. (SHA: 688085), based in China, is set to acquire the...

Company Deals Drug

Shandong Buchang Pharmaceuticals Partners with Lancet for BC001 Licensing in Eurasia

Fineline Cube Aug 15, 2024

Shandong Buchang Pharmaceuticals Co., Ltd. (SHA: 603858), based in China, has announced plans to enter...

Company Drug

Biogen and Eisai Secure UAE Approval for Alzheimer’s Therapy Leqembi

Fineline Cube Aug 15, 2024

Biogen Inc. (NASDAQ: BIIB), based in the U.S., and Japan’s Eisai Co., Ltd. have announced...

Policy / Regulatory

Shaanxi Leads New Provincial Alliance for Volume-Based Procurement of Medical Products

Fineline Cube Aug 15, 2024

The Shaanxi Public Resources Trading Center has announced the formation of a provincial alliance for...

Company Drug

CStone to Manufacture Gavreto Locally Following NMPA Approval, Expanding Market Presence

Fineline Cube Aug 15, 2024

CStone Pharmaceuticals (HKG: 2616), a China-based biopharmaceutical company, has received approval from the National Medical...

Company Medical Device

China’s Sansure Biotech Launches Approved Kit for Alzheimer’s and Cardiovascular Risk Assessment

Fineline Cube Aug 15, 2024

Sansure Biotech Inc. (SHA: 688289), a China-based leader in molecular diagnostics, has secured marketing approval...

Company Drug

Qilu Pharmaceutical Gains Approval for Generic Dasatinib, Expanding CML Treatment Options in China

Fineline Cube Aug 14, 2024

Qilu Pharmaceutical, based in China, has received marketing approval for its generic version of Bristol-Myers...

Company

Eli Lilly Unveils $700 Million R&D Center in Boston to Boost Genetic Medicine Efforts

Fineline Cube Aug 14, 2024

Eli Lilly & Co. (NYSE: LLY) has inaugurated its new R&D center in Boston’s Seaport...

Company Drug

Ascentage Pharma Secures NMPA Approval for Phase III Trial of Lisaftoclax in MDS

Fineline Cube Aug 14, 2024

Ascentage Pharma (HKG: 6855), based in China, has received approval from the National Medical Products...

Company Drug

Enhertu Gains Conditional Approval in China for Advanced HER2-Positive Gastric Cancer

Fineline Cube Aug 14, 2024

Enhertu (trastuzumab deruxtecan), an HER2-targeted antibody-drug conjugate co-developed by AstraZeneca (NASDAQ: AZN, LON: AZN) and...

Company Deals R&D

New Agreement Enhances Myopia Solutions: Hong Kong Polytechnic and Zeiss Collaborate

Fineline Cube Aug 14, 2024

The School of Optometry at Hong Kong Polytechnic University has announced a new cooperation agreement...

Company Medical Device

Lepu Medical’s PeakHeat Vascular Sheath Gains Regulatory Green Light for Market Launch

Fineline Cube Aug 14, 2024

Lepu Medical Technology (Beijing) Co., Ltd (SHE: 300003), a leading provider of cardiovascular disease solutions...

Company Drug Legal / IP

Novartis Intensifies Legal Action Against FDA Over Entresto Generic Approval

Fineline Cube Aug 14, 2024

Novartis Inc. (NYSE: NVS) is intensifying its efforts to thwart the entry of generic competitors...

Company

Sino Biopharmaceutical Reports Record H1 Revenues of RMB 15.87 Billion, Net Profit Soars 139.7%

Fineline Cube Aug 14, 2024

Sino Biopharmaceutical Ltd (HKG: 1177) reported robust financial results for the first half of 2024,...

Company Drug

Wantai Biological’s HPV Vaccine Receives Priority Review from China’s CDE

Fineline Cube Aug 14, 2024

Beijing Wantai Biological Pharmacy Enterprise Co., Ltd (SHA: 603392) has announced that its nine-valent recombinant...

Company Drug

Hengrui Pharmaceuticals Launches Phase II Trial for SHR7280 to Treat Uterine Fibroids

Fineline Cube Aug 14, 2024

Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading Chinese pharmaceutical company, has received approval...

Company Legal / IP R&D

HuidaGene Secures Patent for Innovative CRISPR-Cas12i System in China

Fineline Cube Aug 14, 2024

HuidaGene (Shanghai) Biotechnology Co., Ltd, a China-based biotech firm, has secured patent approval from the...

Company Drug

GSK Initiates Phase III Study for RSV Vaccine in China Following U.S. Approval

Fineline Cube Aug 14, 2024

GSK (NYSE: GSK), the UK-based pharmaceutical giant, has registered a Phase III bridging study for...

Company Drug

Sihuan Pharmaceutical Secures NMPA Approval for First Biosimilars of Novo Nordisk’s Diabetes Drugs

Fineline Cube Aug 14, 2024

Sihuan Pharmaceutical Holdings Group Ltd (HKG: 0460) has secured separate marketing approvals from China’s National...

Posts pagination

1 … 317 318 319 … 669

Recent updates

  • Boehringer Ingelheim and Sino Biopharmaceutical Secure NMPA Conditional Approval for Hernexeos in First-Line HER2-Mutant NSCLC With 76% Response Rate
  • Jenscare’s LuX-Valve Plus Demonstrates 97.8% Efficacy in Tricuspid Regurgitation Reduction in Global EU TRINITY Study 12-Month Follow-Up
  • Bayzed Health Group Partners With MicroPort Subsidiaries to Establish Specialized Cardiovascular and Surgical Robot Centers Across Hospital Network
  • Transcenta and Inhibrx Report 20% Response Rate for Ozekibart in Heavily Pretreated Colorectal Cancer, Following Recent FDA Filing for Chondrosarcoma
  • Sino Medical Sciences Secures EU Label Update for HT Supreme Stent, Enabling One-Month Dual Antiplatelet Therapy
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Boehringer Ingelheim and Sino Biopharmaceutical Secure NMPA Conditional Approval for Hernexeos in First-Line HER2-Mutant NSCLC With 76% Response Rate

Company Medical Device

Jenscare’s LuX-Valve Plus Demonstrates 97.8% Efficacy in Tricuspid Regurgitation Reduction in Global EU TRINITY Study 12-Month Follow-Up

Company Deals

Bayzed Health Group Partners With MicroPort Subsidiaries to Establish Specialized Cardiovascular and Surgical Robot Centers Across Hospital Network

Company Drug

Transcenta and Inhibrx Report 20% Response Rate for Ozekibart in Heavily Pretreated Colorectal Cancer, Following Recent FDA Filing for Chondrosarcoma

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.